The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia

European Neuropsychopharmacology

Volumn 18, Issue 1, 2008, Pages 34-40

  Hamdani, Nora ^a,b   Tabeze, Jean Pierre ^c   Ramoz, Nicolas ^b   Ades, Jean ^a,b   Hamon, Michel ^b   Sarfati, Yves ^d   Boni, Claudette ^b   Gorwood, Philip ^a,b  

^a HÔPITAL LOUIS MOURIER   (France)

^b INSERM   (France)

^c CENTRE HOSPITALIER RENÉ DUBOS   (France)

^d CENTRE HOSPITALIER DE VERSAILLES   (France)

Author keywords

CB1 receptor; CNR1 gene; Pharmacogenetics; Schizophrenia

Indexed keywords

AMISULPRIDE; CANNABINOID 1 RECEPTOR; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; RECEPTOR, CANNABINOID, CB1; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 36849006515     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2007.05.005     Document Type: Article

References (43)

1. Andreasen N.C. Scale for Assessment of Negative Symptoms (SANS) (1984), University of Iowa, Iowa city
2. Andreasson S., Allebeck P., Engstrom A., and Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2 8574 (1987) 1483-1486
3. Armitage P. Test for linear trends in proportions and frequencies. Biometrics 11 (1955) 375-386
4. Arranz M.J., Munro J., Owen M.J., et al. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol. Psychiatry 3 (1998) 61-6f6
5. Arseneault L., Cannon M., Witton J., and Murray R.M. Causal association between cannabis and psychosis: examination of the evidence. Br. J. Psychiatry 184 (2004) 110-117
6. Ballon N., Leroy S., Roy C., et al. (AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population. Pharmacogenomics J. 6 2 (2006) 126-130
7. Barrero F.J., Ampuero I., Morales B., Vives F., de Dios Luna Del Castillo J., Hoenicka J., and Garcia Yebenes J. Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid recepto gene (CNR1). Pharmacogenetics J. 5 (2005) 135-141
8. Bersani G., Orlandi V., Kotzalidis G.D., and Pancheri P. Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. Eur. Arch. Psychiatry Clin. Neurosci. 252 (2002) 86-92
9. Bonnier B., Gorwood P., Hamon M., Sarfati Y., Boni C., and Hardy-Bayle M.C. Bipolar affective disorder with low suicidal risk is associated with 5-HT2A receptor gene polymorphism. Biol. Psychiatry 51 (2002) 762-765
10. Brenner H.D., Dencker S.J., Goldstein M.J., Hubbard J.W., Keegan D.L., Kruger G., Kulhanek F., Liberman R.P., Malm U., and Midha K.K. Defining treatment refractoriness in schizophrenia. Schizophr. Bull. 16 (1990) 551-560
11. Cao Q., Martinez M., Zhang J., Sanders A.R., Badner J.A., Cravchik A., Markey C.J., Beshah E., Guroff J.J., Maxwell M.E., Kazuba D.M., Whiten R., Goldin L.R., Gershon E.S., and Gejman P.V. Suggestive evidence for a schizophrenia susceptibility locus on chromosome 6q and a confirmation in an independent series of pedigrees. Genomics 43 (1997) 1-8
12. Caspi A., Moffitt E., Cannon M., McClay J., Murray R., Harrington H., Taylor A., Arseneault L., Williams B., Braithwaite A., Poulton R., and Craig I.W. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene × environment interaction. Biol. Psychiatry 57 (2005) 1117-1127
13. Comings D.E., Muhleman D., Gade R., et al. Cannabinoid receptor gene (CNR1): association with i.v. drug use. Mol. Psychiatry 2 2 (1997) 161-168
14. Dawson E. Identification of a polymorphic triplet marker for the brain cannabinoid receptor gene: use in linkage and association studies of schizophrenia. Psych. Genet. 5 (1995) S50-S51
15. Dervaux A., Laqueille X., Bourdel M.C., Leborgne M.H., Olie J.P., Loo H., and Krebs M.O. Cannabis and schizophrenia: demographic and clinical correlates. Encéphale 29 1 (2003) 11-17
16. D'Souza D.C., Abi-Saab W.M., Madonick S., Forselius-Bielen K., Doersch A., Braley G., Gueorguieva R., Cooper T.B., and Krystal J.H. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol. Psychiatry 57 (2005) 594-608
17. Gadzicki D., Muller-Vahl K., and Stuhrmann M. A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. Mol. Cell. Probes 13 (1999) 321-323
18. Gorwood P., and Foot E. Introduction on psychopharmacogenetics. In: Gorwood P., and Hamon M. (Eds). Psychopharmacogenetics (2006), Springer, New-York 1-24
19. Green A.I., Tohen M.F., Hamer R.M., Strakowski S.M., Lieberman J.A., Glick I., and Clark W.S. HGDH Research Group. (2004) First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr. Res. 66 (2004) 125-135
20. Gut-Fayand A., Dervaux A., Olie J.P., Loo H., Poirier M.F., and Krebs M.O. Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity. Psychiatry Res. 102 (2001) 65-72
21. Hamdani N., Bonniere M., Ades J., et al. Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics. Neurosci. Lett. 377 1 (2005) 69-74
22. Henquet C., Krabbendam L., Spauwen J., Kaplan C., Wittchen H.U., and van Os J. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 30 7481 (2005) 11
23. Hopfer C.J., Young S.E., Purcell S., Crowley T.J., Stallings M.C., Corley R.P., Rhee S.H., Smolen A., Krauter K., Hewitt J.K., and Ehringer M.A. Cannabis receptor haplotype associated with fewer cannabis dependence symptoms in adolescents. Am. J. Med. Genet., B Neuropsychiatr. Genet. 141 (2006) 895-901
24. Hosmer D.W., and Lemeshow S. Applied Logistic Regression (1980), J. Wiley & Sons, New York
25. Leroy S., Griffon N., Bourdel M.C., Olie J.P., Poirier M.F., and Krebs M.O. Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1. Am. J. Med. Genet. 105 (2001) 749-752
26. Li T., Liu X., Zhu Z.H., et al. No association between (AAT)n repeats in the cannabinoid receptor gene (CNR1) and heroin abuse in a Chinese population. Mol. Psychiatry 5 2 (2000) 128-130
27. Lin C.H., Tsai S.J., Yu Y.W.Y., et al. No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population. Neuroreport 10 (1999) 57-60
28. Marchese G., Casti P., Ruiu S., Saba P., Sanna A., Casu G., and Pani L. Haloperidol, but not clozapine, produces dramatic catalepsy in delta9-THC-treated rats: possible clinical implication. Br. J. Pharmacol. 140 (2003) 520-526
29. Mc Guire P.K., Jones P., Harvey I., Williams M., McGuffin P., and Murray R.M. Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr. Res. 15 (1995) 277-281
30. Muller T.D., Reichwald K., Wermter A.K., et al. No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents. Mol. Genet. Metab. 90 4 (2007) 429-434
31. Nurnberger Jr. J.I., Blehar M.C., Kaufmann C.A., York-Cooler C., Simpson S.G., Harkavy-Friedman J., Severe J.B., Malaspina D., and Reich T. Diagnostic Interview for Genetic studies. Rationale, unique features and training. NIMH genetics initiative. Arch. Gen. Psychiatry 51 (1994) 849-859
32. Onaivi E.S., Leonard C.M., Ishiguro H., Zhang P.W., Lin Z., Akinshola B.E., and Uhl G.R. Endocannabinoids and cannabinoid receptor genetics. Progr. Neurobiol. 66 (2001) 307-344
33. Preuss U.W., Koller G., Zill P., et al. Alcoholism-related phenotypes and genetic variants of the CB1 receptor. Eur. Arch. Psychiatry Clin. Neurosci. 253 6 (2003) 275-280
34. Salanti G., Amountza G., Nitzani E.E., et al. Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur. Hum. Genet. 13 (2005) 840-848
35. Scharfetter J. Psychopharmacogenetics of schizophrenia and psychosis. In: Gorwood P., and Hamon M. (Eds). Psychopharmacogenetics (2006), Springer, New York 101-148
36. Schmidt L.G., Samochowiec J., Finckh U., et al. Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. Drug Alcohol Depend. 65 3 (2002) 221-224
37. Schumacher J., Schulze T.G., Wienker T.F., et al. Pharmacogenetics of the clozapine response. Lancet 356 9228 (2000) 506
38. Simpson S.G., and Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 212 suppl. 44 (1970) 11-19
39. Tsai S.J., Wang Y.C., and Hong C.J. Association study between cannabinoid receptor gene and pathogenesis and psychosis symptoms of mood disorders. Am. J. Med. Genet. 105 (2001) 219-221
40. Ujike H., Takaki M., Nakata K., et al. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol. Psychiatry 7 (2002) 515-518
41. Zaretsky A., Rector N.A., Seeman M.V., et al. Current cannabis use and tardive dyskinesia. Schizophr. Res. 11 (1993) 3-8
42. Zhang P.W., Ishiguro H., Ohtsuki T., et al. Human cannabinoid receptor 1: 5′ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol. Psychiatry 9 (2004) 916-931
43. Zuardi A.W., Rodrigues J.A., and Cunha J.M. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacol. Bull. 104 (1991) 260-264